We are pleased to announce that Lunarsun Pharma's Vonoprazan Fumarate Tablets have obtained NMPA marketing authorization.
Against a rising global burden of acid-related diseases, effective treatments delivering rapid, durable symptom relief remain highly sought-after.
As a P-CAB, Vonoprazan outperforms conventional PPIs with key clinical strengths:
• Faster onset of acid suppression
• Potent, sustained gastric acid control
• Minimal influence from CYP2C19 genetic polymorphism
• Flexible dosing without strict pre-meal intake
Our fully integrated API and finished dosage manufacturing ecosystem ensures stable supply, competitive costs and sustainable commercial cooperation.
We welcome partnerships covering the GCC, Middle East, Africa, Southeast Asia, Latin America and other emerging markets. Reach out to discuss collaboration opportunities.